Abstract

The main clinical indications for intravenous immunoglobulin (IVIG) therapy in Japan are severe bacterial and viral infections as a result of primary and secondary immunodeficiencies, idiopathic thrombocytopenic purpura (ITP), autoimmune diseases, hematologic disorders, acquired immune deficiency syndrome, and Kawasaki disease. Experiences using IVIG to treat patients with severe infectious diseases, Kawasaki disease, and ITP are reported in this article. In patients with severe infections, IVIG showed some clinical benefits. In patients with Kawasaki disease, combined administration of IVIG and aspirin reduced the incidence of coronary artery lesions below that of aspirin alone or without therapy, and persistence of these lesions also decreased in patients who received combination therapy. Organ platelet sequestration, measured with indium 111-labeled platelets, showed a splenic pattern in good responders to IVIG, a hepatic pattern in fair responders, and a splenohepatic pattern in poor responders. These patterns might provide some insight into the use of IVIG. Some reaction mechanisms also are discussed.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.